Tenax Therapeutics, Inc. (TENX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the results of the 2026 Annual Meeting of Stockholders held by Tenax Therapeutics, Inc. on June 2, 2026. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC under the symbol "TENX".
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following proposals were submitted to a vote of security holders:
- Proposal 1: Election of Directors - Stockholders elected seven individuals to the Board of Directors for a one-year term expiring in 2027. All nominees received significant "For" votes, though Michael Davidson received a higher number of "Withheld" votes compared to other nominees.
- Proposal 2: Auditor Ratification - Stockholders ratified the appointment of Cherry Bekaert LLP as the independent registered public accounting firm for the year ending December 31, 2026.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation that all seven director nominees were successfully elected to the Board.
- Verification of the specific vote counts for Michael Davidson, who received 1,814,464 "Withheld" votes, significantly higher than other directors.
- Confirmation that Cherry Bekaert LLP was ratified as the independent auditor for the 2026 fiscal year.
- Review of the total shares represented at the meeting, which totaled approximately 25 million shares across "For", "Withheld", and "Broker Non-Votes" categories.